| 1 | α-Synuclein pathology as a target in neurodegenerative diseases | 28.6 | 48 | Citations (PDF) |
| 2 | Elucidating metabolite and pH variations in stroke through guanidino, amine and amide CEST MRI: A comparative multi-field study at 9.4T and 3T | 4.4 | 2 | Citations (PDF) |
| 3 | Proteome-wide microarray-based screening of PAR-binding proteins | 15.5 | 8 | Citations (PDF) |
| 4 | Cerebellum mitochondrial DNA copy number is increased in Parkinson’s disease | 3.6 | 0 | Citations (PDF) |
| 5 | Interspecies chimerism with human embryonic stem cells generates functional human dopamine neurons at low efficiency | 4.4 | 5 | Citations (PDF) |
| 6 | Protein Translation in the Pathogenesis of Parkinson’s Disease | 4.4 | 7 | Citations (PDF) |
| 7 | Blocking the <scp>Self‐Destruct</scp> Program of Dopamine Neurons through <scp>Macrophage Migration Inhibitory Factor</scp> Nuclease Inhibition | 4.6 | 2 | Citations (PDF) |
| 8 | Poly(<scp>ADP</scp>‐ribose) mediates bioenergetic defects and redox imbalance in neurons following oxygen and glucose deprivation | 0.6 | 10 | Citations (PDF) |
| 9 | Parthanatos: Mechanisms, modulation, and therapeutic prospects in neurodegenerative disease and stroke | 5.1 | 39 | Citations (PDF) |
| 10 | Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein | 13.7 | 32 | Citations (PDF) |
| 11 | Mature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release | 2.4 | 5 | Citations (PDF) |
| 12 | Poly ADP-ribose signaling is dysregulated in Huntington disease | 7.5 | 11 | Citations (PDF) |
| 13 | CalDAG-GEFI acts as a guanine nucleotide exchange factor for LRRK2 to regulate LRRK2 function and neurodegeneration | 10.9 | 1 | Citations (PDF) |
| 14 | The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease | 12.5 | 26 | Citations (PDF) |
| 15 | Apoptotic cell death in disease—Current understanding of the NCCD 2023 | 13.3 | 300 | Citations (PDF) |
| 16 | Farnesol prevents aging-related muscle weakness in mice through enhanced farnesylation of Parkin-interacting substrate | 12.5 | 17 | Citations (PDF) |
| 17 | <scp>PARIS</scp> undergoes liquid–liquid phase separation and poly(<scp>ADP</scp>‐ribose)‐mediated solidification | 5.2 | 8 | Citations (PDF) |
| 18 | Enhanced mTORC1 signaling and protein synthesis in pathologic α-synuclein cellular and animal models of Parkinson’s disease | 12.5 | 49 | Citations (PDF) |
| 19 | CYFIP1 Dosages Exhibit Divergent Behavioral Impact via Diametric Regulation of NMDA Receptor Complex Translation in Mouse Models of Psychiatric Disorders | 5.4 | 17 | Citations (PDF) |
| 20 | Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroupsBrain, 2022, 145, 1757-1762 | 8.4 | 51 | Citations (PDF) |
| 21 | Waiting for PARIS—A Biological Target in Search of a Drug | 3.3 | 3 | Citations (PDF) |
| 22 | Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver | 3.6 | 37 | Citations (PDF) |
| 23 | Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinson’s disease | 10.9 | 23 | Citations (PDF) |
| 24 | STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy | 7.5 | 174 | Citations (PDF) |
| 25 | A high-affinity cocaine binding site associated with the brain acid soluble protein 1 | 7.5 | 7 | Citations (PDF) |
| 26 | Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease | 4.6 | 27 | Citations (PDF) |
| 27 | PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson’s diseaseCell, 2022, 185, 1943-1959.e21 | 33.7 | 97 | Citations (PDF) |
| 28 | Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson’s diseaseNeuron, 2022, 110, 2422-2437.e9 | 11.0 | 171 | Citations (PDF) |
| 29 | AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1 | 13.7 | 7 | Citations (PDF) |
| 30 | Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin | 7.5 | 105 | Citations (PDF) |
| 31 | Poly(ADP-ribose) promotes toxicity of
<i>C9ORF72</i>
arginine-rich dipeptide repeat proteins | 12.5 | 21 | Citations (PDF) |
| 32 | The Absence of Parkin Does Not Promote Dopamine or Mitochondrial Dysfunction in PolgA<sup>D257A/D257A</sup>Mitochondrial Mutator Mice | 3.7 | 19 | Citations (PDF) |
| 33 | APDM gait and balance measures fail to predict symptom progression rate in Parkinson's disease | 2.4 | 3 | Citations (PDF) |
| 34 | Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease | 6.3 | 7 | Citations (PDF) |
| 35 | Mass spectrometry‐based proteomics analysis of human globus pallidus from progressive supranuclear palsy patients discovers multiple disease pathways | 5.5 | 24 | Citations (PDF) |
| 36 | Nanozyme scavenging ROS for prevention of pathologic α-synuclein transmission in Parkinson’s disease | 9.9 | 128 | Citations (PDF) |
| 37 | Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease | 1.7 | 24 | Citations (PDF) |
| 38 | Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture | 25.2 | 368 | Citations (PDF) |
| 39 | Lymphocyte Activation Gene 3 (Lag3) Contributes to α-Synucleinopathy in α-Synuclein Transgenic Mice | 3.4 | 46 | Citations (PDF) |
| 40 | Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease | 17.6 | 123 | Citations (PDF) |
| 41 | The cell biology of Parkinson’s disease | 5.4 | 135 | Citations (PDF) |
| 42 | AIF3 splicing switch triggers neurodegeneration | 14.1 | 8 | Citations (PDF) |
| 43 | Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease | 5.0 | 160 | Citations (PDF) |
| 44 | Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson’s disease | 1.0 | 15 | Citations (PDF) |
| 45 | Targeting Parthanatos in Ischemic Stroke | 2.4 | 51 | Citations (PDF) |
| 46 | Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons | 1.1 | 11 | Citations (PDF) |
| 47 | Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease | 7.5 | 101 | Citations (PDF) |
| 48 | Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in α-Synuclein-Based Mouse Models of Parkinson’s Disease | 3.4 | 52 | Citations (PDF) |
| 49 | Neurodegenerative disorders and gut-brain interactions | 10.6 | 95 | Citations (PDF) |
| 50 | Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis | 6.1 | 33 | Citations (PDF) |
| 51 | PARIS farnesylation prevents neurodegeneration in models of Parkinson’s disease | 12.5 | 58 | Citations (PDF) |
| 52 | Seeking progress in disease modification in Parkinson disease | 2.6 | 13 | Citations (PDF) |
| 53 | Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegenerationBrain, 2021, 144, 3674-3691 | 8.4 | 24 | Citations (PDF) |
| 54 | LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8 | 4.7 | 1 | Citations (PDF) |
| 55 | USP39 promotes non-homologous end-joining repair by poly(ADP-ribose)-induced liquid demixing | 15.5 | 25 | Citations (PDF) |
| 56 | Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection | 15.7 | 29 | Citations (PDF) |
| 57 | TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson’s diseaseNeuron, 2021, 109, 3758-3774.e11 | 11.0 | 46 | Citations (PDF) |
| 58 | Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-γ associated gene regulation | 3.4 | 14 | Citations (PDF) |
| 59 | Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse BrainsENeuro, 2021, 8, ENEURO.0310-21.2021 | 2.1 | 12 | Citations (PDF) |
| 60 | Recent advances in preventing neurodegenerative diseases | 4.1 | 15 | Citations (PDF) |
| 61 | Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementiaBrain, 2020, 143, 234-248 | 8.4 | 225 | Citations (PDF) |
| 62 | Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis | 16.4 | 54 | Citations (PDF) |
| 63 | Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models | 6.3 | 266 | Citations (PDF) |
| 64 | Determinants of seeding and spreading of α-synuclein pathology in the brain | 10.9 | 101 | Citations (PDF) |
| 65 | Microglia and astrocyte dysfunction in parkinson's disease | 5.1 | 331 | Citations (PDF) |
| 66 | Molecular Mediation of Prion-like α-Synuclein Fibrillation from Toxic PFFs to Nontoxic Species | 4.7 | 14 | Citations (PDF) |
| 67 | Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons | 4.4 | 71 | Citations (PDF) |
| 68 | AMPA Receptor Surface Expression Is Regulated by S-Nitrosylation of Thorase and Transnitrosylation of NSF | 6.3 | 18 | Citations (PDF) |
| 69 | Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid | 2.8 | 12 | Citations (PDF) |
| 70 | PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency | 14.1 | 81 | Citations (PDF) |
| 71 | PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease | 14.1 | 432 | Citations (PDF) |
| 72 | Quantitative mass spectrometric analysis of the mouse cerebral cortex after ischemic stroke | 2.3 | 13 | Citations (PDF) |
| 73 | NLRP3 inflammasome activation in dopamine neurons contributes to neurodegeneration in Parkinson’s Disease | 0.6 | 7 | Citations (PDF) |
| 74 | Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain | 0.4 | 2 | Citations (PDF) |
| 75 | Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis | 5.0 | 58 | Citations (PDF) |
| 76 | Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease | 11.0 | 1,215 | Citations (PDF) |
| 77 | Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson’s diseaseBrain, 2019, 142, 2380-2401 | 8.4 | 66 | Citations (PDF) |
| 78 | The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration | 4.6 | 88 | Citations (PDF) |
| 79 | Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia | 9.2 | 236 | Citations (PDF) |
| 80 | Heritability and genetic variance of dementia with Lewy bodies | 5.1 | 38 | Citations (PDF) |
| 81 | Assessment of APOE in atypical parkinsonism syndromes | 5.1 | 26 | Citations (PDF) |
| 82 | Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic ActivitiesENeuro, 2019, 6, ENEURO.0148-19.2019 | 2.1 | 19 | Citations (PDF) |
| 83 | Promising disease-modifying therapies for Parkinson’s disease | 12.5 | 59 | Citations (PDF) |
| 84 | Genetic analysis of neurodegenerative diseases in a pathology cohort | 3.4 | 44 | Citations (PDF) |
| 85 | Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons | 4.1 | 48 | Citations (PDF) |
| 86 | A comprehensive screening of copy number variability in dementia with Lewy bodies | 3.4 | 14 | Citations (PDF) |
| 87 | The AAA + ATPase Thorase is neuroprotective against ischemic injury | 4.7 | 15 | Citations (PDF) |
| 88 | Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease | 2.6 | 137 | Citations (PDF) |
| 89 | DISC1 regulates lactate metabolism in astrocytes: implications for psychiatric disorders | 5.2 | 41 | Citations (PDF) |
| 90 | A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathyBrain, 2018, 141, 651-661 | 8.4 | 59 | Citations (PDF) |
| 91 | Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice | 7.5 | 96 | Citations (PDF) |
| 92 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 | 13.3 | 5,678 | Citations (PDF) |
| 93 | GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers | 7.5 | 166 | Citations (PDF) |
| 94 | Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases | 6.3 | 192 | Citations (PDF) |
| 95 | Domain‐specific cognitive impairment in non‐demented Parkinson's disease psychosis | 2.2 | 11 | Citations (PDF) |
| 96 | Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias | 2.6 | 18 | Citations (PDF) |
| 97 | Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers | 1.5 | 10 | Citations (PDF) |
| 98 | Animal models of neurodegenerative diseases | 17.0 | 513 | Citations (PDF) |
| 99 | Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease | 36.2 | 441 | Citations (PDF) |
| 100 | The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change | 0.2 | 0 | Citations (PDF) |
| 101 | Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease | 25.2 | 254 | Citations (PDF) |
| 102 | α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism | 14.1 | 181 | Citations (PDF) |
| 103 | Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration | 14.1 | 98 | Citations (PDF) |
| 104 | Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease | 2.6 | 43 | Citations (PDF) |
| 105 | Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease | 33.0 | 993 | Citations (PDF) |
| 106 | Neurotoxic reactive astrocytes are induced by activated microglia | 37.9 | 6,890 | Citations (PDF) |
| 107 | Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics | 11.8 | 151 | Citations (PDF) |
| 108 | PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival | 6.3 | 173 | Citations (PDF) |
| 109 | Precision therapy for a new disorder of AMPA receptor recycling due to mutations in
<i>ATAD1</i> | 2.8 | 48 | Citations (PDF) |
| 110 | The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity | 14.1 | 70 | Citations (PDF) |
| 111 | Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes | 4.0 | 64 | Citations (PDF) |
| 112 | T cells from patients with Parkinson’s disease recognize α-synuclein peptides | 37.9 | 803 | Citations (PDF) |
| 113 | Activation mechanisms of the E3 ubiquitin ligase parkin | 3.8 | 52 | Citations (PDF) |
| 114 | Toward the human cellular microRNAome | 4.6 | 165 | Citations (PDF) |
| 115 | Two approaches reveal a new paradigm of ‘switchable or genetics-influenced allele-specific DNA methylation’ with potential in human disease | 7.9 | 26 | Citations (PDF) |
| 116 | Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism | 8.4 | 129 | Citations (PDF) |
| 117 | Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis | 4.7 | 28 | Citations (PDF) |
| 118 | c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential | 3.3 | 84 | Citations (PDF) |
| 119 | Overexpression of Parkinson’s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein PathologyENeuro, 2017, 4, ENEURO.0004-17.2017 | 2.1 | 37 | Citations (PDF) |
| 120 | The NINDS Parkinson's disease biomarkers program | 4.6 | 107 | Citations (PDF) |
| 121 | LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity | 2.0 | 42 | Citations (PDF) |
| 122 | Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3 | 36.2 | 649 | Citations (PDF) |
| 123 | Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes | 2.6 | 23 | Citations (PDF) |
| 124 | Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients | 2.6 | 8 | Citations (PDF) |
| 125 | A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1 | 36.2 | 359 | Citations (PDF) |
| 126 | LRRK2 pathobiology in Parkinson's disease – virtual inclusion | 3.8 | 6 | Citations (PDF) |
| 127 | Association of<i>GBA</i>Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease | 17.6 | 220 | Citations (PDF) |
| 128 | Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1 | 13.7 | 70 | Citations (PDF) |
| 129 | Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity | 12.5 | 87 | Citations (PDF) |
| 130 | Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies | 5.1 | 62 | Citations (PDF) |
| 131 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | 13.7 | 4,989 | Citations (PDF) |
| 132 | <i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in <scp>P</scp>arkinson's disease | 4.6 | 195 | Citations (PDF) |
| 133 | Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration | 10.6 | 166 | Citations (PDF) |
| 134 | Adult Conditional Knockout of PGC-1α Leads to Loss of Dopamine NeuronsENeuro, 2016, 3, ENEURO.0183-16.2016 | 2.1 | 95 | Citations (PDF) |
| 135 | High-Content Genome-Wide RNAi Screen Reveals<i>CCR3</i>as a Key Mediator of Neuronal Cell DeathENeuro, 2016, 3, ENEURO.0185-16.2016 | 2.1 | 19 | Citations (PDF) |
| 136 | (Patho‐)physiological relevance of
<scp>PINK</scp>
1‐dependent ubiquitin phosphorylation | 5.2 | 176 | Citations (PDF) |
| 137 | Lysosomal Enzyme Glucocerebrosidase Protects against Aβ1-42 Oligomer-Induced Neurotoxicity | 2.3 | 17 | Citations (PDF) |
| 138 | <i>PARK10</i>
is a major locus for sporadic neuropathologically confirmed Parkinson disease | 1.0 | 50 | Citations (PDF) |
| 139 | TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson’s disease via CNTFBrain, 2015, 138, 3610-3622 | 8.4 | 126 | Citations (PDF) |
| 140 | Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration | 7.5 | 240 | Citations (PDF) |
| 141 | Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily | 2.9 | 121 | Citations (PDF) |
| 142 | Abberant protein synthesis in G2019S LRRK2<i>Drosophila</i>Parkinson disease-related phenotypes | 2.1 | 20 | Citations (PDF) |
| 143 | <scp>M</scp>sp1/<scp>ATAD</scp>1 maintains mitochondrial function by facilitating the degradation of mislocalized tail‐anchored proteins | 7.3 | 219 | Citations (PDF) |
| 144 | Protein Microarray Characterization of the S-Nitrosoproteome | 3.0 | 58 | Citations (PDF) |
| 145 | LRRK2 pathobiology in Parkinson's disease | 3.8 | 150 | Citations (PDF) |
| 146 | Proneural Transcription Factor Atoh1 Drives Highly Efficient Differentiation of Human Pluripotent Stem Cells Into Dopaminergic Neurons | 4.1 | 43 | Citations (PDF) |
| 147 | A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease | 17.6 | 372 | Citations (PDF) |
| 148 | Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson’s Disease | 33.7 | 265 | Citations (PDF) |
| 149 | Parkin and PINK1: much more than mitophagy | 9.7 | 341 | Citations (PDF) |
| 150 | Early-onset Parkinson's disease due to PINK1 p.Q456X mutation – Clinical and functional study | 2.6 | 48 | Citations (PDF) |
| 151 | Parkin‐independent mitophagy requires <scp>D</scp>rp1 and maintains the integrity of mammalian heart and brain | 7.3 | 414 | Citations (PDF) |
| 152 | Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis | 7.5 | 297 | Citations (PDF) |
| 153 | Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson’s-like movement disorder | 13.7 | 144 | Citations (PDF) |
| 154 | Ganglioside Regulation of AMPA Receptor Trafficking | 3.7 | 59 | Citations (PDF) |
| 155 | MiR-223 regulates the differentiation of immature neurons | 0.0 | 29 | Citations (PDF) |
| 156 | Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration | 5.1 | 71 | Citations (PDF) |
| 157 | Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunities | 6.3 | 525 | Citations (PDF) |
| 158 | The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease | 3.4 | 223 | Citations (PDF) |
| 159 | Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss | 17.0 | 207 | Citations (PDF) |
| 160 | Reprogramming cellular events by poly(ADP-ribose)-binding proteins | 9.4 | 158 | Citations (PDF) |
| 161 | Usp16: key controller of stem cells in Down syndrome | 7.3 | 9 | Citations (PDF) |
| 162 | New synaptic and molecular targets for neuroprotection in Parkinson's disease | 4.6 | 38 | Citations (PDF) |
| 163 | Sulfhydration mediates neuroprotective actions of parkin | 13.7 | 320 | Citations (PDF) |
| 164 | The interplay of microRNA and neuronal activity in health and disease | 3.4 | 52 | Citations (PDF) |
| 165 | LRRK2 Affects Vesicle Trafficking, Neurotransmitter Extracellular Level and Membrane Receptor Localization | 2.3 | 73 | Citations (PDF) |
| 166 | Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments | 3.3 | 39 | Citations (PDF) |
| 167 | Nitric Oxide Synthase Inhibitors | 6.3 | 0 | Citations (PDF) |
| 168 | ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2 | 3.7 | 98 | Citations (PDF) |
| 169 | Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity | 2.9 | 38 | Citations (PDF) |
| 170 | Animal Models of Parkinson's Disease: Vertebrate Genetics | 6.6 | 106 | Citations (PDF) |
| 171 | Neurodegenerative phenotypes in an A53T -synuclein transgenic mouse model are independent of LRRK2 | 2.9 | 96 | Citations (PDF) |
| 172 | MicroRNA-223 is neuroprotective by targeting glutamate receptors | 7.5 | 269 | Citations (PDF) |
| 173 | Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease | 11.4 | 71 | Citations (PDF) |
| 174 | Botch Promotes Neurogenesis by Antagonizing Notch | 7.7 | 69 | Citations (PDF) |
| 175 | Meta‐analysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i> | 6.6 | 288 | Citations (PDF) |
| 176 | Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease | 12.5 | 478 | Citations (PDF) |
| 177 | Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson’s Disease-Related Toxicity in Human Neurons | 3.7 | 142 | Citations (PDF) |
| 178 | PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease | 33.7 | 901 | Citations (PDF) |
| 179 | The AAA+ ATPase Thorase Regulates AMPA Receptor-Dependent Synaptic Plasticity and Behavior | 33.7 | 104 | Citations (PDF) |
| 180 | Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1–Dependent Cell Death (Parthanatos) | 5.4 | 428 | Citations (PDF) |
| 181 | MicroRNAs in Parkinson's disease | 2.0 | 164 | Citations (PDF) |
| 182 | Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2 | 2.3 | 363 | Citations (PDF) |
| 183 | Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death | 33.0 | 206 | Citations (PDF) |
| 184 | Recent Advances in the Genetics of Parkinson's Disease | 6.7 | 400 | Citations (PDF) |
| 185 | A perfect “Match” for in vitro human disease modeling and autologous cell-based transplantation therapy: Generating genetically identical Parkinson's disease and control pluripotent stem cells by precise gene targeting | 4.6 | 0 | Citations (PDF) |
| 186 | Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage | 7.5 | 251 | Citations (PDF) |
| 187 | Enhanced Autophagy from Chronic Toxicity of Iron and Mutant A53T α-Synuclein | 2.2 | 85 | Citations (PDF) |
| 188 | Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models | 2.9 | 131 | Citations (PDF) |
| 189 | Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation | 2.3 | 61 | Citations (PDF) |
| 190 | Neuronal Activity Regulates Hippocampal miRNA Expression | 2.3 | 50 | Citations (PDF) |
| 191 | The role of parkin in familial and sporadic Parkinson's disease | 4.6 | 341 | Citations (PDF) |
| 192 | Contributions of poly(ADP‐ribose) polymerase‐1 and ‐2 to nuclear translocation of apoptosis‐inducing factor and injury from focal cerebral ischemia | 3.8 | 56 | Citations (PDF) |
| 193 | Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease | 33.0 | 358 | Citations (PDF) |
| 194 | NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice | 10.6 | 44 | Citations (PDF) |
| 195 | Synphilin-1 attenuates neuronal degeneration in the A53T -synuclein transgenic mouse model | 2.9 | 81 | Citations (PDF) |
| 196 | Reevaluation of Phosphorylation Sites in the Parkinson Disease-associated Leucine-rich Repeat Kinase 2 | 2.2 | 55 | Citations (PDF) |
| 197 | Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function | 7.5 | 266 | Citations (PDF) |
| 198 | PINK1-dependent recruitment of Parkin to mitochondria in mitophagy | 7.5 | 1,553 | Citations (PDF) |
| 199 | Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia | 2.4 | 20 | Citations (PDF) |
| 200 | GTPase Activity Plays a Key Role in the Pathobiology of LRRK2 | 3.2 | 190 | Citations (PDF) |
| 201 | Genetic Animal Models of Parkinson's Disease | 11.0 | 778 | Citations (PDF) |
| 202 | Functional Identification of Neuroprotective Molecules | 2.3 | 33 | Citations (PDF) |
| 203 | S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease | 7.5 | 150 | Citations (PDF) |
| 204 | CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity | 7.5 | 206 | Citations (PDF) |
| 205 | Outer Mitochondrial Membrane Localization of Apoptosis-Inducing Factor: Mechanistic Implications for Release | 3.4 | 77 | Citations (PDF) |
| 206 | Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease | 3.7 | 57 | Citations (PDF) |
| 207 | Understanding microRNAs in neurodegeneration | 20.8 | 265 | Citations (PDF) |
| 208 | Calpain activation is not required for AIF translocation in PARP‐1‐dependent cell death (parthanatos) | 3.8 | 96 | Citations (PDF) |
| 209 | Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) | 3.7 | 116 | Citations (PDF) |
| 210 | Poly(ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos | 4.0 | 366 | Citations (PDF) |
| 211 | SnapShot: Pathogenesis of Parkinson's DiseaseCell, 2009, 139, 440.e1-440.e2 | 33.7 | 12 | Citations (PDF) |
| 212 | Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With α-Synuclein Inclusions | 1.8 | 29 | Citations (PDF) |
| 213 | Abnormal Localization of Leucine-Rich Repeat Kinase 2 to the Endosomal-Lysosomal Compartment in Lewy Body Disease | 1.8 | 75 | Citations (PDF) |
| 214 | Role of Tuberin in Neuronal Degeneration | 3.4 | 11 | Citations (PDF) |
| 215 | Value of genetic models in understanding the cause and mechanisms of Parkinson’s disease | 4.4 | 43 | Citations (PDF) |
| 216 | Morphometry of the human substantia nigra in ageing and Parkinson’s disease | 9.2 | 172 | Citations (PDF) |
| 217 | Mitochondrial and Nuclear Cross Talk in Cell Death | 4.0 | 339 | Citations (PDF) |
| 218 | Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis | 16.3 | 394 | Citations (PDF) |
| 219 | Parkin mediates the degradation‐independent ubiquitination of Hsp70 | 3.8 | 103 | Citations (PDF) |
| 220 | Non-autonomous cell death in Parkinson's disease | 17.9 | 17 | Citations (PDF) |
| 221 | Autophagy-mediated clearance of aggresomes is not a universal phenomenon | 2.9 | 147 | Citations (PDF) |
| 222 | Advances in Neuronal Cell Death 2007 | 6.0 | 44 | Citations (PDF) |
| 223 | The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2 | 3.7 | 187 | Citations (PDF) |
| 224 | Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes | 15.5 | 391 | Citations (PDF) |
| 225 | Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases | 2.9 | 413 | Citations (PDF) |
| 226 | Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents | 2.2 | 236 | Citations (PDF) |
| 227 | DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase | 7.5 | 452 | Citations (PDF) |
| 228 | Relative Sensitivity of Parkin and Other Cysteine-containing Enzymes to Stress-induced Solubility Alterations | 2.2 | 78 | Citations (PDF) |
| 229 | Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity | 2.9 | 571 | Citations (PDF) |
| 230 | Parkinson's disease genetic mutations increase cell susceptibility to stress: Mutant α-synuclein enhances H2O2- and Sin-1-induced cell death | 3.4 | 55 | Citations (PDF) |
| 231 | A Hierarchical NGF Signaling Cascade Controls Ret-Dependent and Ret-Independent Events during Development of Nonpeptidergic DRG Neurons | 11.0 | 238 | Citations (PDF) |
| 232 | The Role of Stem Cells in Parkinson's Disease | 1.4 | 6 | Citations (PDF) |
| 233 | Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain | 3.8 | 108 | Citations (PDF) |
| 234 | Dynamic and redundant regulation of LRRK2 and LRRK1 expression | 2.1 | 143 | Citations (PDF) |
| 235 | Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain | 2.5 | 141 | Citations (PDF) |
| 236 | MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity | 5.1 | 66 | Citations (PDF) |
| 237 | A Nitric Oxide Signaling Pathway Controls CREB-Mediated Gene Expression in Neurons | 13.3 | 229 | Citations (PDF) |
| 238 | Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases? | 3.4 | 137 | Citations (PDF) |
| 239 | Diagnosis and treatment of Parkinson disease: molecules to medicine | 10.6 | 574 | Citations (PDF) |
| 240 | Kinase activity of mutant LRRK2 mediates neuronal toxicity | 17.0 | 607 | Citations (PDF) |
| 241 | Role of nitric oxide in Parkinson's disease 2006, 109, 33-41 | | 167 | Citations (PDF) |
| 242 | Neuroprotection by pharmacologic blockade of the GAPDH death cascade | 7.5 | 232 | Citations (PDF) |
| 243 | Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death | 7.5 | 697 | Citations (PDF) |
| 244 | Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate | 2.2 | 94 | Citations (PDF) |
| 245 | Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of -Synucleinopathy | 3.7 | 87 | Citations (PDF) |
| 246 | Poly(ADP-ribose) (PAR) polymer is a death signal | 7.5 | 612 | Citations (PDF) |
| 247 | Failures and Successes of Clinical Trials for Parkinson Disease Treatments | 1.8 | 2 | Citations (PDF) |
| 248 | Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations | 3.8 | 117 | Citations (PDF) |
| 249 | Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons | 3.8 | 68 | Citations (PDF) |
| 250 | The involvement of nitric oxide in the enhanced expression of μ
-opioid receptors during intestinal inflammation in mice | 6.3 | 30 | Citations (PDF) |
| 251 | Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin | 2.9 | 218 | Citations (PDF) |
| 252 | Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress | 2.9 | 238 | Citations (PDF) |
| 253 | Bcl-x Is Required for Proper Development of the Mouse Substantia Nigra | 3.7 | 167 | Citations (PDF) |
| 254 | S‐Nitrosylation in Parkinson's Disease and Related Neurodegenerative Disorders | 2.1 | 41 | Citations (PDF) |
| 255 | Identification and Evaluation of NO‐Regulated Genes by Differential Analysis of Primary cDNA Library Expression (DAzLE) | 2.1 | 1 | Citations (PDF) |
| 256 | Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration | 7.5 | 397 | Citations (PDF) |
| 257 | Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation | 3.7 | 521 | Citations (PDF) |
| 258 | Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations | 7.5 | 455 | Citations (PDF) |
| 259 | Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death | 3.7 | 232 | Citations (PDF) |
| 260 | Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function | 2.9 | 203 | Citations (PDF) |
| 261 | Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis | 2.9 | 392 | Citations (PDF) |
| 262 | -Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells | 3.7 | 259 | Citations (PDF) |
| 263 | MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE | 11.4 | 1,182 | Citations (PDF) |
| 264 | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | 7.5 | 1,181 | Citations (PDF) |
| 265 | Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease | 2.6 | 78 | Citations (PDF) |
| 266 | The 350-fold compacted Fugu parkin gene is structurally and functionally similar to human Parkin | 2.3 | 6 | Citations (PDF) |
| 267 | To die or grow: Parkinson's disease and cancer | 9.7 | 118 | Citations (PDF) |
| 268 | Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases | 3.4 | 208 | Citations (PDF) |
| 269 | Recent advances in our understanding of Parkinson's disease | 1.1 | 14 | Citations (PDF) |
| 270 | Mediation of cell death by poly(ADP-ribose) polymerase-1 | 9.1 | 224 | Citations (PDF) |
| 271 | Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity | 2.9 | 333 | Citations (PDF) |
| 272 | Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality | 7.5 | 315 | Citations (PDF) |
| 273 | Loss of locus coeruleus neurons and reduced startle in parkin null mice | 7.5 | 332 | Citations (PDF) |
| 274 | Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE) | 7.5 | 32 | Citations (PDF) |
| 275 | Identification and analysis of plasticity-induced late-response genes | 7.5 | 59 | Citations (PDF) |
| 276 | PARP‐1 gene disruption in mice preferentially protects males from perinatal brain injury | 3.8 | 279 | Citations (PDF) |
| 277 | Deadly Conversations: Nuclear-Mitochondrial Cross-Talk | 2.6 | 177 | Citations (PDF) |
| 278 | Parkin-associated Parkinson’s disease | 2.7 | 132 | Citations (PDF) |
| 279 | Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system | 3.8 | 125 | Citations (PDF) |
| 280 | Apoptosis-Inducing Factor Substitutes for Caspase Executioners in NMDA-Triggered Excitotoxic Neuronal Death | 3.7 | 273 | Citations (PDF) |
| 281 | Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling | 11.4 | 440 | Citations (PDF) |
| 282 | CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation | 2.9 | 679 | Citations (PDF) |
| 283 | Astroglia Induce Cytotoxic Effects on Brain Tumors via a Nitric Oxide-Dependent Pathway Both in Vitro and in Vivo | 2.0 | 13 | Citations (PDF) |
| 284 | Role for the Ubiquitin-Proteasome System in Parkinson's Disease and Other Neurodegenerative Brain Amyloidoses | 3.6 | 52 | Citations (PDF) |
| 285 | New insights into Parkinson?s disease | 3.4 | 37 | Citations (PDF) |
| 286 | A missense mutation (L166P) in DJ‐1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo‐oligomerization | 3.8 | 206 | Citations (PDF) |
| 287 | Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity | 5.1 | 191 | Citations (PDF) |
| 288 | Caught in the Act | 11.0 | 191 | Citations (PDF) |
| 289 | BAK Alters Neuronal Excitability and Can Switch from Anti- to Pro-Death Function during Postnatal Development | 7.7 | 119 | Citations (PDF) |
| 290 | 37-kDa Laminin Receptor Precursor Modulates Cytotoxic Necrotizing Factor 1–mediated RhoA Activation and Bacterial Uptake | 2.2 | 112 | Citations (PDF) |
| 291 | Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age | 2.2 | 143 | Citations (PDF) |
| 292 | Nitric Oxide Protects Cardiac Sarcolemmal Membrane Enzyme Function and Ion Active Transport against Ischemia-induced Inactivation | 2.2 | 40 | Citations (PDF) |
| 293 | Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity | 2.2 | 83 | Citations (PDF) |
| 294 | The Cast of Molecular Characters in Parkinson's Disease | 4.0 | 35 | Citations (PDF) |
| 295 | Apoptosis Inducing Factor and PARP‐Mediated Injury in the MPTP Mouse Model of Parkinson's Disease | 4.0 | 118 | Citations (PDF) |
| 296 | Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice | 7.5 | 798 | Citations (PDF) |
| 297 | The Orphan Nuclear Receptor, Steroidogenic Factor 1, Regulates Neuronal Nitric Oxide Synthase Gene Expression in Pituitary Gonadotropes | 2.5 | 30 | Citations (PDF) |
| 298 | Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death | 5.4 | 442 | Citations (PDF) |
| 299 | Lack of nitric oxide synthase depresses ion transporting enzyme function in cardiac muscle | 2.1 | 35 | Citations (PDF) |
| 300 | Animal Models of PD | 11.0 | 132 | Citations (PDF) |
| 301 | Poly(ADP-Ribose) Polymerase Impairs Early and Long-Term Experimental Stroke Recovery | 6.0 | 127 | Citations (PDF) |
| 302 | The genetics of Parkinson’s disease | 4.4 | 27 | Citations (PDF) |
| 303 | A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism | 3.8 | 92 | Citations (PDF) |
| 304 | Neuroprotective and neurorestorative strategies for Parkinson's disease | 17.0 | 156 | Citations (PDF) |
| 305 | Gene therapy to the rescue in Parkinson's disease | 11.4 | 4 | Citations (PDF) |
| 306 | Identification by mRNA Differential Display of Two Up-regulated Genes as Candidate Mediators of AIDS Dementia | 5.6 | 2 | Citations (PDF) |
| 307 | Reduction of functional N-methyl-d-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA | 3.8 | 8 | Citations (PDF) |
| 308 | Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons | 3.5 | 88 | Citations (PDF) |
| 309 | Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets | 6.6 | 85 | Citations (PDF) |
| 310 | Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease | 33.0 | 733 | Citations (PDF) |
| 311 | Parkin: clinical aspects and neurobiology | 1.0 | 16 | Citations (PDF) |
| 312 | FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle | 7.5 | 139 | Citations (PDF) |
| 313 | Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis | 2.9 | 456 | Citations (PDF) |
| 314 | Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase | 7.5 | 99 | Citations (PDF) |
| 315 | NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase | 3.7 | 211 | Citations (PDF) |
| 316 | Stroke Outcome in Double-Mutant Antioxidant Transgenic Mice | 6.0 | 44 | Citations (PDF) |
| 317 | Requirement for nitric oxide activation of p21
<sup>ras</sup>
/extracellular regulated kinase in neuronal ischemic preconditioning | 7.5 | 319 | Citations (PDF) |
| 318 | Parkinson's disease: clinical manifestations and treatment | 2.7 | 5 | Citations (PDF) |
| 319 | Parkin functions as an E2-dependent ubiquitin– protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1 | 7.5 | 940 | Citations (PDF) |
| 320 | Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB family transcription factor-dependent mechanism | 7.5 | 172 | Citations (PDF) |
| 321 | Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease | 5.1 | 407 | Citations (PDF) |
| 322 | Neuronal ischaemic preconditioning | 11.4 | 57 | Citations (PDF) |
| 323 | New Animal Models for Parkinson's Disease | 33.7 | 92 | Citations (PDF) |
| 324 | Mechanisms and Structural Determinants of HIV-1 Coat Protein, gp41-Induced Neurotoxicity | 3.7 | 72 | Citations (PDF) |
| 325 | Rate and Severity of HIV-Associated Dementia (HAD): Correlations with Gp41 and iNOS | 5.6 | 89 | Citations (PDF) |
| 326 | CELL DEATH AND DISEASES OF THE NERVOUS SYSTEM.Brain, 1999, 122, 995-996 | 8.4 | 0 | Citations (PDF) |
| 327 | Nitric oxide synthase in cardiac sarcoplasmic reticulum | 7.5 | 472 | Citations (PDF) |
| 328 | Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism | 7.5 | 375 | Citations (PDF) |
| 329 | Circadian Locomotor Analysis of Male Mice Lacking the Gene for Neuronal Nitric Oxide Synthase (nNOS–/–) | 2.7 | 29 | Citations (PDF) |
| 330 | Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease | 33.0 | 1,029 | Citations (PDF) |
| 331 | Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions | 25.2 | 493 | Citations (PDF) |
| 332 | Overview of the Pathway and Functions of Nitric Oxide | 0.0 | 0 | Citations (PDF) |
| 333 | Nuclear Targeting of Mutant Huntingtin Increases Toxicity | 2.2 | 179 | Citations (PDF) |
| 334 | Histochemical Analysis of Nitric Oxide Synthase by NADPH Diaphorase Staining | 0.0 | 9 | Citations (PDF) |
| 335 | Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats | 6.0 | 60 | Citations (PDF) |
| 336 | Free Radicals as Mediators of Neuronal Injury | 4.0 | 212 | Citations (PDF) |
| 337 | Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture | 2.9 | 346 | Citations (PDF) |
| 338 | mdx muscle pathology is independent of nNOS perturbation | 2.9 | 105 | Citations (PDF) |
| 339 | Nitric oxide mediates<i>N</i>-methyl-<scp>d</scp>-aspartate receptor-induced activation of p21<sup>ras</sup> | 7.5 | 195 | Citations (PDF) |
| 340 | Nitric Oxide: Diverse Actions in the Central and Peripheral Nervous Systems | 4.4 | 21 | Citations (PDF) |
| 341 | The 12 kD FK506 Binding Protein FKBP12 Is Released in the Male Reproductive Tract and Stimulates Sperm Motility | 5.6 | 23 | Citations (PDF) |
| 342 | Impaired Ovulation in Mice with Targeted Deletion of the Neuronal Isoform of Nitric Oxide Synthase | 5.6 | 22 | Citations (PDF) |
| 343 | NMDAR1 Glutamate Receptor Subunit Isoforms in Neostriatal, Neocortical, and Hippocampal Nitric Oxide Synthase Neurons | 3.7 | 74 | Citations (PDF) |
| 344 | Manganese Superoxide Dismutase Protects nNOS Neurons from NMDA and Nitric Oxide-Mediated Neurotoxicity | 3.7 | 264 | Citations (PDF) |
| 345 | Neuronal (type I) nitric oxide synthase regulates nuclear factorκB activity and immunologic (type II) nitric oxide synthase expression | 7.5 | 192 | Citations (PDF) |
| 346 | Inhibition of Neuronal Nitric Oxide Synthase Increases Aggressive Behavior in Mice | 5.6 | 98 | Citations (PDF) |
| 347 | Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A | 33.0 | 362 | Citations (PDF) |
| 348 | Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans | 33.0 | 148 | Citations (PDF) |
| 349 | Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia | 33.0 | 1,020 | Citations (PDF) |
| 350 | NMDA-R1 subunit of the cerebral cortex co-localizes with neuronal nitric oxide synthase at pre- and postsynaptic sites and in spines | 2.5 | 102 | Citations (PDF) |
| 351 | Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone | 2.5 | 93 | Citations (PDF) |
| 352 | Effects of Nitric Oxide on Neuroendocrine Function and Behavior | 6.2 | 109 | Citations (PDF) |
| 353 | Nitric Oxide Synthase in Models of Focal Ischemia | 6.0 | 590 | Citations (PDF) |
| 354 | NITRIC OXIDE SYNTHASE: Role as a Transmitter/Mediator in the Brain and Endocrine System | 18.7 | 147 | Citations (PDF) |
| 355 | Nitric oxide neurotoxicity | 2.0 | 473 | Citations (PDF) |
| 356 | NITRIC OXIDE ACTIONS IN NEUROCHEMISTRY | 3.5 | 175 | Citations (PDF) |
| 357 | Immunophilin Regulation of Neurotransmitter Release | 5.6 | 65 | Citations (PDF) |
| 358 | Neurovirulent Simian Immunodeficiency Virus Infection Induces Neuronal, Endothelial, and Glial Apoptosis | 5.6 | 67 | Citations (PDF) |
| 359 | Nitric Oxide-Dependent Penile Erection in Mice Lacking Neuronal Nitric Oxide Synthase | 5.6 | 213 | Citations (PDF) |
| 360 | Nitric oxide synthase (NOS) in schizophrenia | 0.9 | 73 | Citations (PDF) |
| 361 | Neurobiology of Nitric Oxide | 1.0 | 268 | Citations (PDF) |
| 362 | Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase | 6.6 | 70 | Citations (PDF) |
| 363 | Effects of Central Inhibition of Nitric Oxide Synthase on Focal Cerebral Ischemia in Rats | 4.7 | 35 | Citations (PDF) |
| 364 | Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase | 37.9 | 613 | Citations (PDF) |
| 365 | REVIEW ■ : Nitric Oxide: Actions and Pathological Roles | 4.4 | 101 | Citations (PDF) |
| 366 | Widespread expression of Huntington's disease gene (IT15) protein product | 11.0 | 500 | Citations (PDF) |
| 367 | Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. | 7.5 | 296 | Citations (PDF) |
| 368 | Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains | 6.6 | 537 | Citations (PDF) |
| 369 | Nitric oxide mediates the formation of synaptic connections in developing and regenerating olfactory receptor neurons | 11.0 | 233 | Citations (PDF) |
| 370 | The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin | 2.3 | 144 | Citations (PDF) |
| 371 | gp120 neurotoxicity in primary cortical cultures | 1.7 | 25 | Citations (PDF) |
| 372 | Secondary mechanisms in neuronal trauma | 3.7 | 145 | Citations (PDF) |
| 373 | Molecular Mechanisms of Nitric Oxide Actions in the Brain<sup>a</sup> | 4.0 | 106 | Citations (PDF) |
| 374 | Reactive nitrogen intermediates: Effector molecules of immune-mediated inflammatory nervous system disorders? | 6.6 | 0 | Citations (PDF) |
| 375 | Possible Origins and Distribution of Immunoreactive Nitric Oxide Synthase-Containing Nerve Fibers in Cerebral Arteries | 4.7 | 377 | Citations (PDF) |
| 376 | Neurotransmitter release regulated by nitric oxide in PC-12 cells and brain synaptosomes | 3.6 | 110 | Citations (PDF) |
| 377 | Enhanced expression of nitric oxide synthase by rat retina following pterygopalatine parasympathetic denervation | 2.5 | 52 | Citations (PDF) |
| 378 | Targeted disruption of the neuronal nitric oxide synthase geneCell, 1993, 75, 1273-1286 | 33.7 | 1,345 | Citations (PDF) |
| 379 | Risk Factors for the Neurologic Complications Associated With Aortic Aneurysms | 6.8 | 33 | Citations (PDF) |
| 380 | High brain densities of the immunophilin FKBP colocalized with calcineurin | 37.9 | 355 | Citations (PDF) |
| 381 | Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease | 6.6 | 178 | Citations (PDF) |
| 382 | Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants | 2.5 | 22 | Citations (PDF) |
| 383 | Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase | 11.0 | 1,402 | Citations (PDF) |
| 384 | Thrombotic microangiopathy isolated to the central nervous system | 6.6 | 2 | Citations (PDF) |
| 385 | Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons | 3.4 | 37 | Citations (PDF) |
| 386 | Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine | 2.8 | 62 | Citations (PDF) |
| 387 | Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen | 4.5 | 80 | Citations (PDF) |
| 388 | Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase | 3.4 | 69 | Citations (PDF) |
| 389 | Dopamine D-2 auto- and postsynaptic receptors in the nigrostriatal system of the rat brain: localization by quantitative autoradiography with [3H]sulpiride | 4.3 | 70 | Citations (PDF) |
| 390 | Presynaptic and postsynaptic D1 dopamine receptors in the nigrostriatal system of the rat brain: a quantitative autoradiographic study using the selective D1 antagonist [3H]SCH 23390 | 2.5 | 84 | Citations (PDF) |
| 391 | Chronic administration of sertraline, a selective serotonin uptake inhibitor, decreased the density of β-adrenergic receptors in rat frontoparietal cortex | 2.5 | 30 | Citations (PDF) |
| 392 | Evidence that [3H]forskolin binding in the substantia nigra is intrinsic to a striatal-nigral projection: An autoradiographic study of rat brain | 1.9 | 27 | Citations (PDF) |
| 393 | Autoradiographic Evidence of [3H]SCH 23390 Binding Site; in Human Prefrontal Cortex (Brodmann's Area 9) | 3.8 | 34 | Citations (PDF) |
| 394 | Quantitative autoradiographic localization of D-1 dopamine receptors in the rat brain: Use of the iodinated ligand [125I]SCH 23982 | 1.9 | 54 | Citations (PDF) |
| 395 | Quantitative autoradiographic evidence for axonal transport of imipramine receptors in the central nervous system of the rat | 1.9 | 32 | Citations (PDF) |
| 396 | Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa | 1.6 | 24 | Citations (PDF) |
| 397 | Title is missing! 0 | | 3 | Citations (PDF) |
| 398 | Lewy body dementia promotion by air pollutants | 36.2 | 17 | Citations (PDF) |
